Company
Headquarters: New York, NY, United States
Employees: 26
€49.61 Billion
EUR as of Jan. 1, 2026
US$58.26 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally. The company operates through Ferrous Minerals and Base Metals segments. The Ferrous Minerals segment produces and extracts iron ore and pellets, manganese, ferroalloys, and other ferrous products; and provides related logistic services. The Base Metals segment produces and extracts nickel and its by-products, such as gold, silver, cobalt, precious metals, and others, as well as copper. The company was formerly known as Companhia Vale do Rio Doce and changed its name to Vale S.A. in May 2009. Vale S.A. was founded in 1942 and is headquartered in Rio de Janeiro, Brazil.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | €33.45 B |
| EBITDA | €11.73 B |
| Gross Profit TTM | €11.64 B |
| Profit Margin | 14.15% |
| Operating Margin | 32.32% |
| Quarterly Revenue Growth | 7.00% |
Conversion Labs, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CVLB